Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent signed~* Patients both sexes, age between 30 and 60 years~* Diagnosis of prediabetes according American Diabetes Association criteria (fasting blood glucose levels between 100-126 mg/dl; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose between 140-199 mg/dl; or glycosylated hemoglobin between 5.7-6.4%)~* Diagnosis of prehypertension according (JNC8) Eighth Joint National Committee blood pressure between 120-139/ 80-89 mmHg.~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to ingredients of intervention~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Diabetes diagnosis~* Previous treatment for glucose or blood pressure Triglycerides ≥400 mg/dL~* Total cholesterol ≥240 mg/dL~* History of cardiovascular disease~* Worker per shift / night

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, one per day before breakfast during 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).